Hydromethylthionine mesylate for Alzheimer's disease

Hydromethylthionine mesylate is currently in clinical development for the treatment of Alzheimer’s disease (AD). AD is a progressive neurological disease which is caused by loss of function and death of nerve cells in the brain. It is the most common type of dementia. One of the early symptoms of AD is mild cognitive impairment where a person may have difficulty with memory, reasoning, and attention. In the early stages the difficulties are significant enough to be noticed by the patient and their family or friends but not so severe as to affect their ability to carry out some everyday activities. There is currently no cure for AD and current treatment options aim to relieve the symptoms (including cognitive impairment) rather than stop progression of the disease.